Verastem | VSTM - Operating Expenses


Verastem reported $63.57M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Alaunos Therapeutics USD 1.01M 175K Mar/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Curis USD 11.52M 2.5M Mar/2026
Cytokinetics USD 207.8M 7.22M Jun/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
Incyte USD 973.64M 4.65B Jun/2026
Laboratory Of America USD 3.27B 146.9M Jun/2026
Novartis USD 10.2B 912M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
TG Therapeutics USD 218.66M 48.54M Jun/2026
Verastem USD 63.57M 4.56M Mar/2026